From January 1, 2023 to March 31, 2023, the company has repurchased 0 shares, representing 0% for ?0 million. With this, the company has completed the repurchase of 2,052,808 shares, representing 3.72% for ?135.01 million under the buyback announced on November 3, 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
82.8 EUR | -1.95% | -1.78% | +37.54% |
04-02 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
03-12 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+37.54% | 4.72B | |
+33.43% | 690B | |
+26.43% | 546B | |
-5.12% | 358B | |
+19.59% | 323B | |
+4.89% | 287B | |
+14.32% | 235B | |
+5.79% | 199B | |
-9.49% | 195B | |
+4.26% | 161B |
- Stock Market
- Equities
- ROVI Stock
- News Laboratorios Farmaceuticos Rovi, S.A.
- Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021.